Neuro-ophthalmic Complications in Patients Treated with CTLA-4 and PD-1/PD-L1 Checkpoint Blockade Inhibition (Video)
Creator
Eduardo Nicolás Seleme; Michel Sun; John Chen; Anastasia Zekeridou; Elia Sechi; Ryan Walsh; Johanna Beebe; Osama Sabbagh; Luis Mejico; Sean Gratton; Philip Skidd; David Bellows; Julie Falardeau; Clare Fraser; Cecilia Cappelen-Smith; Scott Haines; Bahareh Hassanzadeh; Meagan Seay; Prem Subramanian; Zoë Williams; Lynn Gordon
Affiliation
(EL) (JB) (LM) Vanderbilt Eye Institute, Nashville, Tennessee
Subject
Optic Neuritis; Myasthenia; Ocular Motility; Orbit; Chemotherapy and Radiation Injury
Description
In recent years, the use of CTLA-4 and PD-1/PD-L1 checkpoint blockade inhibitors have proven to be effective and become increasingly widespread treatment options for metastatic melanoma and other cancers by enhancing autologous anti-tumor immune responses. Immune related ophthalmologic complications have been reported in association with checkpoint inhibitor usebut remain incompletely characterized. This study seeks to investigate and further characterize the Neuro-ophthalmic adverse effects from immune checkpoint blockade treatment.
Date
2020-03
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2020 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2020: Scientific Platform Session I
